Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.48 |
| ▸ | FABP7 | O15540 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 2/20 | 0.41 |
| ▸ | MDM4 | O15151 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL31454960 | 0.92 | KMT2A (0.49) | KMT2AEPHX2FABP5FABP7CA1 | |
| SCHEMBL4970478 | 0.88 | KMT2A (0.53) | KMT2AEPHX2FABP5FABP7CA1 | |
| SCHEMBL17744918 | 0.85 | KMT2A (0.51) | KMT2AEPHX2FABP5FABP7CA1 | |
| SCHEMBL1436990 | 0.84 | KMT2A (0.56) | KMT2AEPHX2FABP5FABP7CA1 | |
| SCHEMBL1504724 | 0.83 | KMT2A (0.49) | KMT2AEPHX2FABP5FABP7CA1 | |
| SCHEMBL27873417 | 0.83 | KMT2A (0.55) | KMT2AEPHX2FABP5FABP7CA1 | |
| Hydrochloric Acid SCHEMBL2174098 | 0.83 | KMT2A (0.55) | KMT2AEPHX2FABP5FABP7CA1 | |
| Bromide SCHEMBL15671138 | 0.83 | KMT2A (0.55) | KMT2AEPHX2FABP5FABP7CA1 | |
| SCHEMBL1162471 | 0.83 | KMT2A (0.55) | KMT2AEPHX2FABP5FABP7CA1 | |
| SCHEMBL3683870 | 0.81 | KMT2A (0.52) | KMT2AEPHX2FABP5FABP7CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12497460-B2 | Anti-MSR1 antibodies and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| US-20250064954-A1 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2025-02-27 | — | — | US | disclosed |
| US-12156913-B2 | Biodegradable liquogel and pH sensitive nanocarriers | NORTH CAROLINA CENTRAL UNIVERSITY (US) | 2024-12-03 | — | — | US | disclosed |
| CN-118955604-A | Steroid compounds and antibody conjugates thereof | 里珍纳龙药品有限公司 | 2024-11-15 | — | — | CN | disclosed |
| US-20240342299-A1 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | REGENERON PHARMA (US) | 2024-10-17 | — | — | US | disclosed |
| US-12070506-B2 | Steroids and antibody-conjugates thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2024-08-27 | — | — | US | disclosed |
| CN-112004557-B | Steroid compounds and antibody conjugates thereof | 里珍纳龙药品有限公司 | 2024-07-30 | — | — | CN | disclosed |
| US-20230079407-A1 | ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. | 2023-03-16 | — | — | US | disclosed |
| US-11377502-B2 | Anti-MSR1 antibodies and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-20210284655-A1 | LIBRARIES OF HETEROARYL-CONTAINING MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | CYCLENIUM PHARMA INC. (CA) | 2021-09-16 | — | — | US | disclosed |
| EP-1871343-A2 | MICELLE COMPOSITION OF POLYMER AND PASSENGER DRUG | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20060251710-A1 | Micelle composition of polymer and passenger drug | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-11-09 | — | — | US | disclosed |
| WO-2006110862-A2 | MICELLE COMPOSITION OF POLYMER AND PASSENGER DRUG | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2006-10-19 | — | — | WO | disclosed |
| US-7067620-B2 | Antibacterial agents | THERAVANCE, INC. (US) | 2006-06-27 | — | — | US | disclosed |
| CN-1249081-C | Glycopeptide derivatives or pharmaceutical compositions containing them | ADVANCED MEDICINE INC (US) | 2006-04-05 | — | — | CN | disclosed |
| US-20050171010-A1 | NOVEL ANTIBACTERIAL AGENTS | CUMBERLAND PHARMACEUTICALS INC. | 2005-08-04 | — | — | US | disclosed |
| US-6518242-B1 | Derivatives of glycopeptide antibacterial agents | THERAVANCE, INC. | 2003-02-11 | — | — | US | disclosed |
| CN-1315961-A | Glycopeptide derivatives and pharmaceutical compositions containing same | ADVANCED MEDICINE INC (US) | 2001-10-03 | — | — | CN | disclosed |
| EP-1060189-A1 | DERIVATIVES OF GLYCOPEPTIDE ANTIBACTERIAL AGENTS | Advanced Medicine, Inc. (US) | 2000-12-20 | — | — | EP | disclosed |
| WO-1999042476-A1 | NOVEL ANTIBACTERIAL AGENTS | ADVANCED MEDICINE, INC. (US) | 1999-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240342299-A1 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | SERPINA6, NR3C1, NR3C2 | KMT2A 4385/4885EPHX2 2214/4885FABP5 414/4885 |
| US-12070506-B2 | Steroids and antibody-conjugates thereof | SERPINA6, NR3C1, NR3C2 | KMT2A 4385/4885EPHX2 2214/4885FABP5 414/4885 |
| US-20050171010-A1 | NOVEL ANTIBACTERIAL AGENTS | ENGASE, GALE, MGAM | KMT2A 4630/4885EPHX2 2301/4885FABP5 632/4885 |
| US-20230079407-A1 | ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF | CD47, MSR1, LDLR | KMT2A 710/4885EPHX2 4662/4885FABP5 419/4885 |
| US-20210284655-A1 | LIBRARIES OF HETEROARYL-CONTAINING MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | NCOA3, VDR, GRK3 | KMT2A 3787/4885EPHX2 3147/4885FABP5 871/4885 |
| US-20250064954-A1 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | SERPINA6, NR3C1, NR3C2 | KMT2A 4385/4885EPHX2 2214/4885FABP5 414/4885 |
| US-12497460-B2 | Anti-MSR1 antibodies and methods of use thereof | CD47, MSR1, LDLR | KMT2A 710/4885EPHX2 4662/4885FABP5 419/4885 |
| US-11377502-B2 | Anti-MSR1 antibodies and methods of use thereof | CD47, MSR1, LDLR | KMT2A 710/4885EPHX2 4662/4885FABP5 419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.